Novartis Sales Rise Despite Generic Drug Competition in U.S.

Core Insights - The pharma major reported strong results for the year 2025 but has guided towards a decline in core operating profit for the current year [1] Financial Performance - The company achieved robust financial results in 2025, indicating a strong performance in that fiscal year [1] - Despite the strong results in 2025, the company anticipates a decrease in core operating profit for the current year, suggesting potential challenges ahead [1]